Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

Xiajie WEN; Guixin LI; Jie LI; Huiying RAO; Jidong JIA; Fengmin LU

doi:10.3969/j.issn.1001-5256.2021.07.002

Volume 37 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(7): 1495-1500

PDF( 1978 KB)

Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

DOI: 10.3969/j.issn.1001-5256.2021.07.002

1.
Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
2.
Institute of Hepatology, People's Hospital, Peking University, Beijing 100044, China
3.
Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
4.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received Date: 2021-04-23
Accepted Date: 2021-04-23
Published Date: 2021-07-20

Abstract

Abstract

There is still a large number of patients with chronic hepatitis B virus (HBV) infection in China, which greatly affects the health of Chinese people. With the change in lifestyle, the incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing year by year in China. Some clinical studies have shown that there is a relatively low incidence rate of chronic HBV infection with NAFLD, while there are still reports on NAFLD in promoting the progression of chronic hepatitis B-related diseases. Based on literature search and review, this article attempts to investigate the interaction between HBV replication, abnormal lipid metabolism, and fatty liver disease in patients with chronic hepatitis B and NAFLD, in order to provide ideas for HBV antiviral treatment and prevention of NAFLD.
- Hepatitis B Virus,
- Hepatitis B,
- Non-alcoholic Fatty Liver Disease,
- Virus Replication

FullText(HTML)

非酒精性脂肪性肝病(NAFLD)是以体内甘油三酯异常蓄积于肝脏为特征，在远期可进展为肝硬化甚至肝细胞癌，在过去20年间我国NAFLD患病率迅速增长^[1]，现已取代病毒性肝炎成为我国第一大慢性肝病^[2]。现行指南推荐通过改善生活方式来达到预防疾病的目的，但并无可量化的标准以作为参考。理想心血管健康行为和因素包括四个生活方式因素(不吸烟、BMI＜25 kg/m²、积极体育活动和符合指南的最佳饮食)，以及三个生物因素(未治疗的总胆固醇＜200 mg/dL，未治疗的空腹血糖＜100 mg/dL，未治疗血压＜120/80 mmHg)^[3]，有多项研究^[4-6]已证实促进理想心血管健康行为和因素可有助于降低癌症、糖尿病及慢性肾病等疾病的发病风险。以往研究^[7]也通过横断面研究的方法证实健康生活方式与NAFLD呈负向关联。依托开滦研究的数据资料，通过队列研究的方法，探究理想心血管健康行为和因素对NAFLD发病的影响。

1. 资料与方法

1.1 观察对象

本研究数据源于开滦研究(注册号：ChiCTR-TNRC-11001489)。2006年7月—2007年6月(以下简称2006年度)，由开滦总医院及所属10家分院对开滦集团职工进行了第1次健康体检，以后每2年进行1次随访，现已完成5次。收集流行病学调查内容、人体测量学指标、生化指标检测以及包括肝脏超声资料在内的腹部超声检查。选择2006年度体检数据作为基线资料。在随后的随访中流行病学调查内容、人体测量学指标及生化指标检测均同第1次健康体检。参加并完成2006年度开滦集团健康体检的在职及离退休职工共计101 510例。入选标准：(1)年满18周岁，参加2006年度健康体检者；(2)基线资料中心血管健康行为和因素7项数据全部完整者；(3)基线肝脏超声资料完整者；(4)至少完成1次随访者。排除标准：(1)长期大量饮酒者(折合乙醇量男性≥140 g/周，女性≥70 g/周)；(2)基线资料中患有NAFLD、肝炎、肝硬化者；(3)虽然参加该次随访，但肝脏超声资料缺失者；(4)既往患有恶性肿瘤、心脑血管疾病者。

1.2 资料收集

流行病学调查、人体测量学及血清生化检测等资料的收集方法见本课题组已发表的文章^[8]。流行病学收集的数据资料包括体育锻炼、吸烟、饮酒情况等，人体测量学收集资料包括身高、体质量等，血清生化检测收集资料包括血脂、血糖、转氨酶等。

1.3 NAFLD的确定

参照《非酒精性脂肪性肝病防治指南(2018年更新版)》^[9]定义。由具有多年临床经验的影像科医生为体检者进行空腹腹部超声检查。采用PHILIPS公司HD-15彩色超声诊断仪，低频探头，频率3.5 MHz。收集资料起自2006年7月1日，截止至2013年12月31日，未发生事件者随访截止时间为死亡时间或末次随访时间，发生事件者随访截止时间为NAFLD确诊时间。

1.4 理想心血管健康行为及因素的定义

根据美国心脏协会2010年提出的心血管健康指标评分标准，包括吸烟、体育锻炼、BMI、饮食、血脂、血压、血糖，每项指标分为3个等级(理想、一般、差)。由于2006年启动的开滦研究调查问卷中未列入“蔬菜摄入量”的健康指标，但考虑到盐摄入水平对我国人群的影响及《心脏病学实践2010——规范化治疗》^[10]中提出的健康标准，本研究将美国心脏协会健康行为定义中的“蔬菜摄入量”改为“食盐摄入量”，根据喜好归类为“喜淡”“一般”“喜咸”。

1.5 相关定义

根据2006年度开滦职工收入情况，将家庭人均收入定义为：一般收入(＜1000元)、高收入(＞1000元)；受教育程度：高等教育水平(大学及以上学历)、非高等教育水平(高中及以下学历)。

1.6 分组依据

采用Huffman等人创建的简易复合式评分系统——心血管健康评分(CHS)评估个体心血管健康情况^[11]。心血管健康指标的赋值：差为0分，一般为1分，理想为2分，分值范围：0~14分。将研究对象按照CHS评分情况进行四分位分组：第一分位组(CHS≤7分，Q1组)、第二分位组(7分＜CHS≤9分，Q2组)、第三分位组(9分＜CHS≤10分，Q3组)、第四分位组(CHS＞10分，Q4组)。

1.7 伦理学审查

本研究遵照赫尔辛基宣言，并通过开滦总医院伦理委员会审批，批号：200605，所有观察对象均签署知情同意书。

1.8 统计学方法

应用SAS 9.4统计软件进行数据分析。正态分布的计量资料以x±s表示，多组间比较采用单因素方差分析；偏态分布的计量资料采用M(P₂₅~P₇₅)表示，多组间比较采用Kruskal-Wallis H检验。计数资料组间比较采用χ²检验。采用人年发病率描述4组间NAFLD的发病情况。采用Cox比例风险模型分析不同CHS水平对新发NAFLD的HR和95%CI。使用限制性立方样条曲线(restricted cubic spline regression，RCS)计算CHS作为连续型变量和NAFLD发病风险的剂量反应关系。并对CHS的每一组分与NAFLD的发病影响重复进行了Cox回归模型分析。P＜0.05为差异有统计学意义。

2. 结果

2.1 一般情况

参加2006年度健康体检者101 510例，按照纳入标准共纳入85 025例观察对象，排除基线资料中过量饮酒者15 450例，患有NAFLD、病毒性肝炎、肝硬化者16 904例，排除随访过程中肝脏超声资料缺失者780例，排除既往恶性肿瘤、心脑血管疾病者1380例，最终纳入统计分析的观察对象共计50 511例，平均(49.15±12.53)岁，其中男37 953例，女12 558例。根据CHS将观察对象进行四分位分组，其中Q1组10 057例，Q2组17 732例，Q3组10 321例，Q4组12 401例，4组间观察人群年龄、男性比例、HDL-C、TG、ALT、Hs-CRP水平及家庭收入、受教育程度、理想BMI、理想血压、理想血糖、理想总胆固醇、理想吸烟、理想体育锻炼、理想饮食比例比较差异均有统计学意义(P值均＜0.05)(表 1)。

表 1 观察人群不同分组情况的一般情况比较

指标	Q1组(n=10 057)	Q2组(n=17 732)	Q3组(n=10 321)	Q4组(n=12 401)	统计值	P值
年龄(岁)	50.38±11.44	50.72±12.28	49.40±12.73	45.70±12.92	F=451.17	＜0.001
男性[例(%)]	9336(92.83)	14 723(83.03)	7492(72.59)	6402(51.62)	χ²=598.24	＜0.001
HDL-C(mmol/L)	1.53±0.39	1.54±0.40	1.54±0.39	1.52±0.36	F=7.77	＜0.001
TG (mmol/L)	1.54(1.09~2.33)	1.23(0.90~1.77)	1.10(0.79~1.51)	0.93(0.68~1.27)	χ²=52.83	＜0.001
UA (mmol/L)	305.12±87.04	284.01±77.00	369.96±74.26	255.54±71.72	F=825.22	＜0.001
ALT(U/L)	19.00(13.00~26.00)	18.00(12.00~23.00)	17.00(12.00~23.00)	15.00(11.00~21.00)	χ²=883.24	＜0.001
Hs-CRP (mg/L)	0.91(0.40~2.14)	0.70(0.29~1.82)	0.60(0.21~1.64)	0.50(0.20~1.40)	χ²=908.36	＜0.001
高等教育程度[例(%)]	760(7.56)	1202(6.78)	839(8.13)	1791(14.44)	χ²=584.02	＜0.001
高家庭收入[例(%)]	791(7.87)	1156(6.52)	623(6.04)	994(8.02)	χ²=51.74	＜0.001
理想BMI[例(%)]	1430(14.22)	5957(33.59)	5915(57.31)	10 337(83.36)	χ²=126.43	＜0.001
理想血压[例(%)]	523(5.20)	2505(14.13)	2545(24.66)	7278(58.69)	χ²=105.98	＜0.001
理想血糖[例(%)]	6440(64.04)	15 421(86.97)	9806(95.01)	12 210(98.46)	χ²=66.56	＜0.001
理想总胆固醇[例(%)]	3503(34.83)	10 357(58.41)	7658(74.20)	10 841(87.42)	χ²=737.19	＜0.001
理想吸烟[例(%)]	2710(26.95)	10 610(59.84)	8248(79.91)	11 537(93.03)	χ²=119.82	＜0.001
理想体育锻炼[例(%)]	1004(9.98)	2337(13.18)	1427(13.83)	2306(18.60)	χ²=362.34	＜0.001
理想饮食[例(%)]	570(5.67)	1280(7.22)	933(9.04)	1909(15.39)	χ²=795.99	＜0.001
注：Hs-CRP，超敏-C反应蛋白。

下载: 导出CSV

| 显示表格

2.2 不同CHS水平对NAFLD的发病影响

64 836例观察对象平均随访5.58年，共发生15 265例NAFLD，男性10 969例，女性4296例。在总人群中，4组观察对象的人年发病率分别为77.88/千人年、61.33/千人年、46.37/千人年、33.69/千人年，随着CHS水平的增加，NAFLD的发病情况依次降低。

Cox比例风险模型结果显示：在校正年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度后，CHS每增加1分，NAFLD的发病风险比为0.73(0.72~0.74)。CHS与NAFLD发病风险的剂量-反应关系，RCS结果表明(取25%、50%和75% 3个截点)：CHS连续型变量与NAFLD呈非线性关系(P＜0.05)。将CHS的不同分组代入模型，校正相同的混杂因素后，以Q1组为对照组，Q2组、Q3组、Q4组发生NAFLD的风险逐渐降低(P for trend＜0.05)，Q2组发病风险比为0.78(0.74~0.81)，Q 3组发病风险比为0.57(0.54~0.59)，Q4组发病风险比为0.38(0.36~0.41)。在男女性及年龄的分层分析中，也得到了类似的结果(P for trent＜0.05)(表 2)。

表 2 心血管健康评分影响NAFLD发病的Cox风险比例模型

项目	例数	发病例数	发病率(/千人年)	HR(95%CI)	P值
总体
Q1组	10 057	4104	77.88
Q2组	17 732	5956	61.33	0.78(0.74~0.81)	＜0.001
Q3组	10 321	2737	46.37	0.57(0.54~0.59)	＜0.001
Q4组	12 401	2468	33.69	0.38(0.36~0.41)	＜0.001
性别					＜0.001¹⁾
男
Q1组	9336	3655	73.94
Q2组	14 723	4492	54.84	0.77(0.73~0.80)	＜0.001
Q3组	7492	1725	39.79	0.57(0.53~0.60)	＜0.001
Q4组	6402	1097	28.92	0.52(0.39~0.45)	＜0.001
女
Q1组	721	449	137.57
Q2组	3009	1464	96.32	0.79(0.71~0.88)	＜0.001
Q3组	2829	1012	64.65	0.56(0.50~0.63)	＜0.001
Q4组	5999	1371	38.81	0.37(0.33~0.42)	＜0.001
年龄					＜0.001¹⁾
≤45岁
Q1组	3106	1164	67.79
Q2组	5584	1773	55.02	0.83(0.77~0.90)	＜0.001
Q3组	3751	890	39.91	0.58(0.53~0.64)	＜0.001
Q4组	6192	1016	27.14	0.37(0.34~0.41)	＜0.001
＞45岁
Q1组	6951	2940	82.75
Q2组	12 148	4183	64.46	0.76(0.72~0.79)	＜0.001
Q3组	6570	1847	50.29	0.56(0.53~0.60)	＜0.001
Q4组	6209	1452	40.54	0.42(0.39~0.45)	＜0.001
注：模型校正了年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度。1)P for interaction＜0.001。

下载: 导出CSV

| 显示表格

2.3 CHS各组分对NAFLD的发病影响

Cox比例风险模型结果显示：在校正年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度后，理想BMI、理想血压、理想血糖、理想总胆固醇、理想饮食是NAFLD发病的保护因素，理想吸烟、理想体育锻炼对NAFLD的发病无影响(表 3)。

表 3 CHS各组成影响NAFLD发病的Cox风险比例模型

组成	HR(95%CI)	P值
理想BMI[例(%)]	0.37(0.36~0.39)	＜0.001
理想血压[例(%)]	0.72(0.69~0.75)	＜0.001
理想血糖[例(%)]	0.80(0.77~0.84)	＜0.001
理想总胆固醇[例(%)]	0.86(0.83~0.89)	＜0.001
理想吸烟[例(%)]	0.98(0.94~1.02)	0.524
理想体育锻炼[例(%)]	1.02(0.98~1.08)	0.595
理想饮食[例(%)]	0.94(0.90~0.99)	0.006
注：模型校正了年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度。

下载: 导出CSV

| 显示表格

3. 讨论

随着我国经济水平和生活水平的不断提高，我国NAFLD的患病率同西方发达国家一样，也在呈现不断攀升的局面，主要的影响因素为营养过剩、缺乏体育锻炼等不良生活方式。根据我国流行病学调查数据^[12]显示，城乡居民中仅有0.7%的个体拥有全部的6种健康生活方式，这也就意味着居民在健康生活方式方面急需改进。

本研究发现CHS评分越高，NAFLD的发病风险越低。在校正混杂因素后，CHS每增加1分，NAFLD的发病风险下降至0.73。RCS结果显示，CHS与NAFLD发病风险之间的剂量-反应关系呈曲线效应，并非简单直线变化。因此将CHS以四分位分组代入Cox比例风险模型中，与Q1组相比，Q2组、Q3组、Q4组NAFLD的发病风险分别下降至0.78倍、0.57倍、0.38倍。这提示CHS对NAFLD的发病风险起到保护作用。由于NAFLD的发病存在性别与年龄差异，且CHS对NAFLD的影响与性别、年龄存在交互作用，因此按性别和年龄分层后重复进行Cox模型分析。在性别分层分析中，发现女性观察对象未来发生NAFLD的风险较男性更低，这种性别间的差异可能与女性观察对象雌激素的保护作用有关。另外，在年龄分层分析中，青年人群中第四分位组的观察对象未来发生NAFLD的风险低于同水平中老年组，虽然NAFLD的发病年龄越发提前，但早期保持健康的生活方式，对于NAFLD的预防将十分有效。

以往研究结论也支持保持健康的生活方式可以降低NAFLD的发生风险。一项来自我国上海地区包括3424例观察的队列研究^[13]结果显示：在5年的随访过程中，与0~2项理想心血管健康行为和因素的观察对象相比，拥有6~7项指标的观察对象发生NAFLD的风险降低66%(OR=0.34，95%CI：0.22~0.51)。Liu等^[14]的结果也证实CHS评分越高，NAFLD的发生风险越低。另一项来自韩国的队列研究^[15]也得到了类似的结论。但与以往研究不同的是，本研究未简单根据理想心血管健康行为和因素的指标个数进行分组，而是将评分更加细化，考虑到了人群“一般”情况的存在；另外，本研究纳入统计分析的样本量更大，有着更充分的随访时长，因此本结果更具有说服力。

本研究对理想心血管健康行为和因素中的每一组分对NAFLD的发病影响也分别进行了分析，发现保持理想的BMI水平发生NAFLD可降低至0.37，而且保持理想的BMI水平较其他组分对NAFLD的影响更大，所起到的保护作用更强。在本研究中，未能发现理想体育锻炼及理想吸烟与NAFLD间的关联，这可能与这些数据的收集是来自观察对象的自我报告有关。体育锻炼一方面可以减轻肝细胞凋亡和增加胰岛素敏感性来改善NAFLD病情严重程度；另一方面可使机体维持着一个较正常的BMI水平，有助于预防NAFLD的发生^[16]。在本研究中，还发现理想饮食也可降低NAFLD的发病，虽然采用盐摄入量来代替蔬菜摄入量作为参考指标，但盐摄入量与NAFLD的发病关系密切，Shen等^[17]的研究发现与低食盐摄入量(＜6 g/d)的人群相比，中食盐摄入量(6~9 g/d)及高食盐摄入量(≥9 g/d)的观察对象NAFLD的发病风险均有增加。

目前的流行病学研究更加强调健康生活方式的综合效应而非某单一因素的影响，通过主动改善生活方式，积极增加健康行为因素的数量并长期坚持，对于减轻NAFLD造成的疾病负担至关重要。

本研究使用了回顾性队列研究方法，样本量大且失访率低，随访时间长，观察对象依从性较好。但本研究亦存在一定的局限：首先，本研究NAFLD的诊断主要以腹部超声为依据，尽管肝组织活检是目前NAFLD诊断的金标准，但由于活检的有创性，不适于体检人群的流行病学调查。腹部超声检查无创，且方便、快捷便于实施，具有较高灵敏度和特异度。其次，本研究吸烟、饮酒、饮食、体育锻炼等行为特征通过调查对象自报获得，可能存在信息偏倚；最后，基线数据仅使用单次收集的资料，这可能会导致结果不稳定。因此，未来进一步的随访及病因学的探索将有助于精准探讨理想心血管健康行为和因素对NAFLD发病的影响。

References(51)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[3]	SHI JP, FAN JG, WU R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol, 2008, 23(9): 1419-1425. DOI: 10.1111/j.1440-1746.2008.05531.x.
[4]	JOO EJ, CHANG Y, YEOM JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 65(3): 828-835. DOI: 10.1002/hep.28917.
[5]	ZHONG GC, WU YL, HAO FB, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis[J]. J Viral Hepat, 2018, 25(7): 842-852. DOI: 10.1111/jvh.12878.
[6]	WANG B, LI W, FANG H, et al. Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis[J]. Mol Med Rep, 2019, 19(1): 320-326. DOI: 10.3892/mmr.2018.9619.
[7]	XU QH, JIE YS, SHU X, et al. Relationship of fatty liver with HBV infection, hyperlipidemia and abnormal alanine aminotransferase[J]. Chin J Exp Clin Virol, 2009, 23(2): 141-143. DOI: 10.3760/cma.j.issn.1003-9279.2009.02.022. 徐启桓, 揭育胜, 舒欣, 等. 脂肪肝与HBV感染、高脂血症及ALT异常的相关分析[J]. 中华实验和临床病毒学杂志, 2009, 23(2): 141-143. DOI: 10.3760/cma.j.issn.1003-9279.2009.02.022
[8]	DANE DS, CAMERON CH, BRIGGS M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis[J]. Lancet, 1970, 1(7649): 695-698. DOI: 10.1016/s0140-6736(70)90926-8.
[9]	YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
[10]	WANG WX, LI M, WU X, et al. HNF1 is critical for the liver-specific function of HBV enhancer Ⅱ[J]. Res Virol, 1998, 149(2): 99-108. DOI: 10.1016/s0923-2516(98)80085-x.
[11]	LI M, XIE Y, WU X, et al. HNF3 binds and activates the second enhancer, ENⅡ, of hepatitis B virus[J]. Virology, 1995, 214(2): 371-378. DOI: 10.1006/viro.1995.0046.
[12]	CHEN M, HIENG S, QIAN X, et al. Regulation of hepatitis B virus ENI enhancer activity by hepatocyte-enriched transcription factor HNF3[J]. Virology, 1994, 205(1): 127-132. DOI: 10.1006/viro.1994.1627.
[13]	GUIDOTTI LG, EGGERS CM, RANEY AK, et al. In vivo regulation of hepatitis B virus replication by peroxisome proliferators[J]. J Virol, 1999, 73(12): 10377-10386. DOI: 10.1128/JVI.73.12.10377-10386.1999.
[14]	REESE VC, OROPEZA CE, MCLACHLAN A. Independent activation of hepatitis B virus biosynthesis by retinoids, peroxisome proliferators, and bile acids[J]. J Virol, 2013, 87(2): 991-997. DOI: 10.1128/JVI.01562-12.
[15]	TANG H, MCLACHLAN A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism[J]. Proc Natl Acad Sci U S A, 2001, 98(4): 1841-1846. DOI: 10.1073/pnas.041479698.
[16]	BARDENS A, DÖRING T, STIELER J, et al. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner[J]. Cell Microbiol, 2011, 13(4): 602-619. DOI: 10.1111/j.1462-5822.2010.01557.x.
[17]	CHOU SF, TSAI ML, HUANG JY, et al. The dual role of an ESCRT-0 component HGS in HBV transcription and naked capsid secretion[J]. PLoS Pathog, 2015, 11(10): e1005123. DOI: 10.1371/journal.ppat.1005123.
[18]	JIANG B, HIMMELSBACH K, REN H, et al. Subviral hepatitis B virus filaments, like infectious viral particles, are released via multivesicular bodies[J]. J Virol, 2015, 90(7): 3330-3341. DOI: 10.1128/JVI.03109-15.
[19]	BREMER CM, BUNG C, KOTT N, et al. Hepatitis B virus infection is dependent on cholesterol in the viral envelope[J]. Cell Microbiol, 2009, 11(2): 249-260. DOI: 10.1111/j.1462-5822.2008.01250.x.
[20]	ABDUL-WAHED A, GUILMEAU S, POSTIC C. Sweet Sixteenth for ChREBP: Established roles and future goals[J]. Cell Metab, 2017, 26(2): 324-341. DOI: 10.1016/j.cmet.2017.07.004.
[21]	HAMILTON JA, KAMP F. How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids?[J]. Diabetes, 1999, 48(12): 2255-2269. DOI: 10.2337/diabetes.48.12.2255.
[22]	LUO J, YANG H, SONG BL. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol, 2020, 21(4): 225-245. DOI: 10.1038/s41580-019-0190-7.
[23]	BOUCHARD MJ, SCHNEIDER RJ. The enigmatic X gene of hepatitis B virus[J]. J Virol, 2004, 78(23): 12725-12734. DOI: 10.1128/JVI.78.23.12725-12734.2004.
[24]	KIM K, KIM KH, KIM HH, et al. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha[J]. Biochem J, 2008, 416(2): 219-230. DOI: 10.1042/BJ20081336.
[25]	KIM KH, SHIN HJ, KIM K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology, 2007, 132(5): 1955-1967. DOI: 10.1053/j.gastro.2007.03.039.
[26]	KIM JY, SONG EH, LEE HJ, et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways[J]. J Mol Biol, 2010, 397(4): 917-931. DOI: 10.1016/j.jmb.2010.02.016.
[27]	PORSTMANN T, SANTOS CR, GRIFFITHS B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth[J]. Cell Metab, 2008, 8(3): 224-236. DOI: 10.1016/j.cmet.2008.07.007.
[28]	XIAO CX, YANG XN, HUANG QW, et al. ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells[J]. Cancer Lett, 2013, 330(1): 67-73. DOI: 10.1016/j.canlet.2012.11.030.
[29]	OEHLER N, VOLZ T, BHADRA OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493. DOI: 10.1002/hep.27159.
[30]	SHLOMAI A, PARAN N, SHAUL Y. PGC-1alpha controls hepatitis B virus through nutritional signals[J]. Proc Natl Acad Sci U S A, 2006, 103(43): 16003-16008. DOI: 10.1073/pnas.0607837103.
[31]	CURTIL C, ENACHE LS, RADREAU P, et al. The metabolic sensors FXRα, PGC-1α, and SIRT1 cooperatively regulate hepatitis B virus transcription[J]. FASEB J, 2014, 28(3): 1454-1463. DOI: 10.1096/fj.13-236372.
[32]	KIM HY, CHO HK, KIM HH, et al. Oxygenated derivatives of cholesterol promote hepatitis B virus gene expression through nuclear receptor LXRα activation[J]. Virus Res, 2011, 158(1-2): 55-61. DOI: 10.1016/j.virusres.2011.03.010.
[33]	ZENG J, WU D, HU H, et al. Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes[J]. Hepatology, 2020, 72(6): 1935-1948. DOI: 10.1002/hep.31217.
[34]	DU L, MA Y, LIU M, et al. Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo[J]. Virol J, 2017, 14(1): 96. DOI: 10.1186/s12985-017-0765-x.
[35]	HU W, WANG X, DING X, et al. MicroRNA-141 represses HBV replication by targeting PPARA[J]. PLoS One, 2012, 7(3): e34165. DOI: 10.1371/journal.pone.0034165.
[36]	WAKUI Y, INOUE J, UENO Y, et al. Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone[J]. Biochem Biophys Res Commun, 2010, 396(2): 508-514. DOI: 10.1016/j.bbrc.2010.04.128.
[37]	YOON S, JUNG J, KIM T, et al. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication[J]. Virology, 2011, 409(2): 290-298. DOI: 10.1016/j.virol.2010.10.024.
[38]	ZHANG Z, PAN Q, DUAN XY, et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J]. J Gastroenterol Hepatol, 2012, 27(12): 1858-1864. DOI: 10.1111/j.1440-1746.2012.07268.x.
[39]	HU D, WANG H, WANG H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446. DOI: 10.1007/s12072-018-9877-7.
[40]	LIN YL, SHIAO MS, METTLING C, et al. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion[J]. Virology, 2003, 314(1): 253-260. DOI: 10.1016/s0042-6822(03)00403-3.
[41]	DOROBANTU C, MACOVEI A, LAZAR C, et al. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein[J]. J Virol, 2011, 85(24): 13373-13383. DOI: 10.1128/JVI.05423-11.
[42]	HORIE M, TSUCHIYA Y, HAYASHI M, et al. NB-598: A potent competitive inhibitor of squalene epoxidase[J]. J Biol Chem, 1990, 265(30): 18075-18078. http://europepmc.org/abstract/MED/2211682
[43]	TATEMATSU K, TANAKA Y, SUGIYAMA M, et al. Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication[J]. J Med Virol, 2011, 83(4): 587-593. DOI: 10.1002/jmv.21970.
[44]	ZHANG JY, DUAN ZP, ZHANG JL, et al. Research advances in the role of sphingolipids in HCV and HBV life cycles[J]. Chin J Hepatol, 2016, 24(12): 945-947. DOI: 10.3760/cma.j.issn.1007-3418.2016.12.016. 张金艳, 段钟平, 张金兰, 等. 鞘脂在HCV和HBV生命周期中作用的研究进展[J]. 中华肝脏病杂志, 2016, 24(12): 945-947. DOI: 10.3760/cma.j.issn.1007-3418.2016.12.016.
[45]	HUANG Q, LEI H, DING L, et al. Stimulated phospholipid synthesis is key for hepatitis B virus replications[J]. Sci Rep, 2019, 9(1): 12989. DOI: 10.1038/s41598-019-49367-8.
[46]	PARK ES, LEE JH, HONG JH, et al. Phosphatidylcholine alteration identified using MALDI imaging MS in HBV-infected mouse livers and virus-mediated regeneration defects[J]. PLoS One, 2014, 9(8): e103955. DOI: 10.1371/journal.pone.0103955.
[47]	HUANG H, SUN Z, PAN H, et al. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B[J]. Sci Rep, 2016, 6: 30853. DOI: 10.1038/srep30853.
[48]	LI H, ZHU W, ZHANG L, et al. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment[J]. Sci Rep, 2015, 5: 8421. DOI: 10.1038/srep08421.
[49]	GAVILANES F, GONZALEZ-ROS JM, PETERSON DL. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins[J]. J Biol Chem, 1982, 257(13): 7770-7777. http://www.ncbi.nlm.nih.gov/pubmed/7085648
[50]	OKAMURA H, NIO Y, AKAHORI Y, et al. Fatty acid biosynthesis is involved in the production of hepatitis B virus particles[J]. Biochem Biophys Res Commun, 2016, 475(1): 87-92. DOI: 10.1016/j.bbrc.2016.05.043.
[51]	ESSER K, LUCIFORA J, WETTENGEL J, et al. Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle[J]. Antiviral Res, 2018, 151: 4-7. DOI: 10.1016/j.antiviral.2018.01.001.

Relative Articles

[1]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[2]	Liang XU, Ping LI, Lin CHEN, Yuqiang FU. Natural history and non-invasive diagnosis and clinical management of chronic HBV infection overlapping with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1501-1507. doi: 10.3969/j.issn.1001-5256.2021.07.003
[3]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[4]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[5]	Jun JIANG, Fuzhong WU, Deyang WANG. Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent[J]. Journal of Clinical Hepatology, 2021, 37(11): 2545-2545. doi: 10.3969/j.issn.1001-5256.2021.11.010
[6]	Ling QING, Weiqiang HUANG, Xiaohe LI, Feng CHEN, Yingxia LIU. Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2075-2080. doi: 10.3969/j.issn.1001-5256.2021.09.015
[7]	Yang DING, Xiaoguang DOU. How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(11): 2546-2547. doi: 10.3969/j.issn.1001-5256.2021.11.011
[8]	Lina JIANG, Wei Li, Jingmin ZHAO. Current status and perspectives of the clinical and basic research on concomitant chronic hepatitis B virus infection and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1489-1494. doi: 10.3969/j.issn.1001-5256.2021.07.001
[9]	Yanhua TANG, Xingyu LU, Jian SUN. Chronic hepatitis B virus infection with nonalcoholic fatty liver disease: Problems faced by antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1508-1514. doi: 10.3969/j.issn.1001-5256.2021.07.004
[10]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[11]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[12]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[13]	Lu BingJie, Chen Xi, Sun MingYu. Application of lipid-regulating drugs in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2444-2448. doi: 10.3969/j.issn.1001-5256.2017.12.043
[14]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[15]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
[16]	Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301.
[17]	Qiu RongYuan, He ShengSong, Chen Feng, Pang Ran. Construction of eukaryotic expression vector of P21 mutation type by nuclear location signal and its effect on virus replication in HepG2.2.15 Cells[J]. Journal of Clinical Hepatology, 2010, 26(4): 387-391.
[18]	Chen Sheng, Lin ChaoShuang. The relationship between liver function and immune system and viral replication in patients with viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 94-95.
[19]	Yang XiaoJuan, Wu GuoRong, Lu ZhongHua, Pei Hao, Qian JinJuan. Clinical signification of detecting PreS;antigen for identifying viral replication in patients with HB without HbeAg[J]. Journal of Clinical Hepatology, 2007, 23(5): 340-341.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	王钰莹，张继佳，吴照科，朱慎慎. 老年冠心病患者营养不良的影响因素及Nomogram预测模型的构建. 海南医学. 2025(01): 34-40 .
2.	刘文丽，丁彦淳，蔡靖姣. 心血管健康行为和健康因素对2型糖尿病人群脑梗死事件的影响研究. 当代护士(下旬刊). 2024(12): 111-115 .
3.	曾冠男，陈容容，卢世云. 成年人Life's Simple 7和非酒精性脂肪性肝病之间的关联. 中国医药指南. 2023(21): 29-32 .
4.	李庚，张国新，凡华，李恒涛，汤卫兵. 短期强化他汀治疗ST段抬高型心肌梗死的效果. 长春中医药大学学报. 2023(10): 1138-1141 .
5.	迟玉玉，刘丹，刘涛，郁建阳，周晓燕，吴寿岭. 理想心血管健康指标评分对恶性肿瘤发病的影响. 中西医结合心脑血管病杂志. 2023(22): 4210-4214 .
6.	徐淑倩，朱敬丽，刘梦莹，沈冲，于蕾，陆慧. 成人心血管健康评分、生命质量与心脑血管病的关系研究. 中国心血管病研究. 2023(11): 966-971 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2032) PDF downloads(381)

Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

DOI: 10.3969/j.issn.1001-5256.2021.07.002